All In Biotech

NDA 019891 · Rhodes Pharms

Dilaudid

Hydromorphone Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Dec 7, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

290

61 Phase 3, 22 recruiting

FAERS reports

91,827

85,087 serious, 28,204 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE See full prescribing information for complete boxed warning . Ensure accuracy when prescribing, dispensing, and administering hydromorphone hydrochloride oral solution. Dosing errors due to confusion between mg and mL can result in accidental overdose and death. ( 2.1 , 5.1 ) Hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets expose users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.2 ) Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory...

What it is approved for

From the label in effect May 14, 2026.

Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets contain hydromorphone, an opioid agonist, and are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.2 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.2) ] , reserve opioid analgesics, including hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

Mechanism: Hydromorphone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of hydromorphone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 7, 1992 Original approval · Type 3 - New Dosage Form REMS
1 products under this application
  • DILAUDID · HYDROMORPHONE HYDROCHLORIDE 5MG/5ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydromorphone" as an intervention, any sponsor and status, largest first.

All 290 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence35,119
  • overdose23,079
  • pain22,354
  • emotional distress17,705
  • death14,926
  • drug withdrawal syndrome14,329
  • toxicity to various agents10,084
  • nausea4,811
  • drug ineffective4,543
  • fatigue3,652
  • vomiting3,601
  • off label use3,489

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004287
2005320
2006383
2007437
2008438
2009647
2010866
2011980
20121,400
20131,246
20141,380
20151,964
20162,588
20173,922
201823,055
20192,735
20208,703
202117,398
202215,695
20232,349
20242,204
20251,754
20261,074

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dilaudid (Hydromorphone HCl)

2024 spending

$350K

Beneficiaries

253

757 claims

Per beneficiary

$1,384

$4.18 per unit

View as table
YearSpending
2020$1,667,512
2021$1,420,060
2022$1,121,656
2023$905,514
2024$350,270

Part B: Dilaudid* (Hydromorphone HCL/PF*) · HCPCS J1171

2024 spending

$99K

Beneficiaries

932

2,056 claims

Per beneficiary

$106

2024 ASP limit $0.09 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$98,543

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 571 on PubMed

Sponsor: Rhodes Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.